Clinical trial
A Multi-center, Double-blind, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of CpG 1018/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Individuals Aged 18 Years and Older in China
NCT04954131 is registered in ClinicalTrials.gov with Zhejiang Clover Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Double-blind, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of CpG 1018/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Individuals Aged 18 Years and Older in China
- Lead sponsor
- Zhejiang Clover Biopharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 10, 2021
- Completion date
- November 15, 2022
- Enrollment
- 766 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.